Arrowhead Pharmaceuticals said its RNA interference drug Redemplo looked safer as well as effective in two late-stage triglyceride trials, positioning the program as a potential competitive counterweight to Ionis Pharmaceuticals’ work in the same metabolic space. The update comes as triglyceride-lowering therapies continue to vie for differentiation on tolerability and magnitude of lipid reductions. The Munich meeting backdrop (#ESC26) highlighted the urgency around comparative safety profiles for cardiometabolic medicines, where class effects and adverse-event rates can determine uptake. Arrowhead’s claim of a safety advantage ties directly into label readiness and payer acceptance. While efficacy signals were also described as supportive, the narrative emphasis was on the tolerability picture—particularly important for long-term, medication-anchored cardiovascular risk reduction strategies.